Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Positron Emission Tomography01:29

Positron Emission Tomography

Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body being...
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
Radiological Investigation III: Pulmonary Angiogram and PET Scan01:13

Radiological Investigation III: Pulmonary Angiogram and PET Scan

Radiological investigations are paramount in the diagnosis and management of various pulmonary diseases. Two essential investigations are the Pulmonary Angiogram and the Positron Emission Tomography (PET) Scan.
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Preclinical characterization of a novel FAP-targeted PET tracer, [<sup>68</sup>Ga]Ga-CB6NT-FAPI.

Nuclear medicine and biology·2026
Same author

Preclinical evaluation and dosimetry of [<sup>64</sup>Cu/<sup>67</sup>Cu]Cu-NGUL for PSMA-targeted prostate cancer theranostics.

Nuclear medicine and biology·2025
Same author

Performance of a deep convolutional neural network to classify crystal structures using selected area electron beam diffraction patterns containing lattice defect information.

RSC advances·2024
Same author

NADH elevation during chronic hypoxia leads to VHL-mediated HIF-1α degradation via SIRT1 inhibition.

Cell & bioscience·2023
Same author

Phase I Clinical Trial of Prostate-Specific Membrane Antigen-Targeting <sup>68</sup>Ga-NGUL PET/CT in Healthy Volunteers and Patients with Prostate Cancer.

Korean journal of radiology·2022
Same author

KSNM60: The History of Radiopharmaceutical Sciences in Korea.

Nuclear medicine and molecular imaging·2022

Related Experiment Video

Updated: May 19, 2026

Tumor Hypoxia Assessment: In Vivo 3D Oxygen Imaging Through Electron Paramagnetic Resonance
07:07

Tumor Hypoxia Assessment: In Vivo 3D Oxygen Imaging Through Electron Paramagnetic Resonance

Published on: February 14, 2025

Hypoxia imaging agents labeled with positron emitters.

Lathika Hoigebazar1, Jae Min Jeong

  • 1Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, Korea.

Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer
|August 25, 2012
PubMed
Summary

Positron emission tomography (PET) imaging agents for detecting tumor hypoxia are crucial for cancer therapy. While several agents exist, improving hypoxia PET imaging remains a challenge due to low uptake in hypoxic tissues.

More Related Videos

Multi-Tracer Studies of Brain Oxygen and Glucose Metabolism Using a Time-of-Flight Positron Emission Tomography-Computed Tomography Scanner
08:36

Multi-Tracer Studies of Brain Oxygen and Glucose Metabolism Using a Time-of-Flight Positron Emission Tomography-Computed Tomography Scanner

Published on: June 7, 2024

Synthesis of 68Ga Core-doped Iron Oxide Nanoparticles for Dual Positron Emission Tomography /(T1)Magnetic Resonance Imaging
07:26

Synthesis of 68Ga Core-doped Iron Oxide Nanoparticles for Dual Positron Emission Tomography /(T1)Magnetic Resonance Imaging

Published on: November 20, 2018

Related Experiment Videos

Last Updated: May 19, 2026

Tumor Hypoxia Assessment: In Vivo 3D Oxygen Imaging Through Electron Paramagnetic Resonance
07:07

Tumor Hypoxia Assessment: In Vivo 3D Oxygen Imaging Through Electron Paramagnetic Resonance

Published on: February 14, 2025

Multi-Tracer Studies of Brain Oxygen and Glucose Metabolism Using a Time-of-Flight Positron Emission Tomography-Computed Tomography Scanner
08:36

Multi-Tracer Studies of Brain Oxygen and Glucose Metabolism Using a Time-of-Flight Positron Emission Tomography-Computed Tomography Scanner

Published on: June 7, 2024

Synthesis of 68Ga Core-doped Iron Oxide Nanoparticles for Dual Positron Emission Tomography /(T1)Magnetic Resonance Imaging
07:26

Synthesis of 68Ga Core-doped Iron Oxide Nanoparticles for Dual Positron Emission Tomography /(T1)Magnetic Resonance Imaging

Published on: November 20, 2018

Area of Science:

  • Nuclear medicine
  • Radiochemistry
  • Oncology

Background:

  • Hypoxia imaging is vital for cancer therapy.
  • Positron emission tomography (PET) is a key imaging modality.
  • Various hypoxia imaging agents have been developed.

Purpose of the Study:

  • To review existing PET hypoxia imaging agents.
  • To discuss the development of nitroimidazole derivatives.
  • To highlight challenges in current hypoxia imaging.

Main Methods:

  • Review of radiolabeled nitroimidazole derivatives like FMISO, FETNIM, FAZA, EF-5, and FETA.
  • Discussion of (68)Ga-labeled nitroimidazole derivatives.
  • Consideration of (64)Cu-ATSM as a hypoxia imaging agent.

Main Results:

  • Several [(18)F]-labeled nitroimidazoles have been developed.
  • (68)Ga-labeled derivatives offer an alternative to cyclotron-dependent isotopes.
  • (64)Cu-ATSM shows rapid distribution but faces production cost limitations.

Conclusions:

  • Despite advancements, hypoxia PET imaging requires further improvement.
  • Low blood flow in hypoxic tissues limits agent uptake.
  • Continued development of novel PET tracers is necessary.